Bio-Rad Laboratories (FRA:BUWA) Long-Term Debt: €695 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
71 GF Score
Price €266.00
GF Value €277.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Long-Term Debt?

Bio-Rad Laboratories FRA:BUWA +1.45% 71 Long-Term Debt is €695 Mil as of Mar. 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 71/100 and a GF Value™ of €277.82 (Fairly Valued). The stock has 5 warning signs investors should review.

Bio-Rad Laboratories's Long-Term Debt for the quarter that ended in Mar. 2026 was €695 Mil.

Bio-Rad Laboratories's quarterly Long-Term Debt increased from Sep. 2025 (€1,024 Mil) to Dec. 2025 (€1,027 Mil) but then declined from Dec. 2025 (€1,027 Mil) to Mar. 2026 (€695 Mil).

Bio-Rad Laboratories's annual Long-Term Debt increased from Dec. 2023 (€1,100 Mil) to Dec. 2024 (€1,146 Mil) but then declined from Dec. 2024 (€1,146 Mil) to Dec. 2025 (€1,027 Mil).

Bio-Rad Laboratories  (FRA:BUWA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Bio-Rad Laboratories Long-Term Debt Related Terms

Bio-Rad Laboratories Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Long-Term Debt Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.31 1,130.63 1,099.58 1,146.38 1,027.36

Bio-Rad Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,110.65 1,041.35 1,023.59 1,027.36 694.51
FRA:BUWA
71GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €695 Mil mean?
Bio-Rad Laboratories (FRA:BUWA) has a Long-Term Debt of €695 Mil as of Mar. 2026.
Is Bio-Rad Laboratories' Long-Term Debt too high?
Bio-Rad Laboratories' current Long-Term Debt is €695 Mil. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Long-Term Debt compare to GKOS and BRKR?
Bio-Rad Laboratories' Long-Term Debt of €695 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Bio-Rad Laboratories's current Long-Term Debt is €695 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €277.82, compared to a current price of €266.00 — trading 4.3% below its estimated fair value. The current Long-Term Debt is €695 Mil. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Long-Term Debt is €695 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €266.00 is trading 4.3% below its estimated GF Value™ of €277.82. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for FRA:BUWA:

  • Long-Term Debt: €695 Mil
  • GF Value™: €277.82 vs. price of €266.00 (4.3% below fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score

Get the complete analysis for FRA:BUWA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€266.00
Price
€277.82
GF Value